A risk-adapted approach to acute GVHD treatment: Are we there yet?

Research output: Contribution to journalReview articlepeer-review

22 Scopus citations


Acute GVHD (aGVHD) is an immunologic complication of allogeneic hematopoietic cell transplantation (HCT) that can range from mild to life-threatening. Models to predict patients at risk of poor outcomes have been developed using both clinical and laboratory data, and the time to test these models in clinical trials has arrived. However, each modeling method has its potential advantages and limitations. In this mini-review, we summarize recent refinements to these models. We also suggest avenues for improving risk stratification through further studies of a patient's healing capacity and predisposition to endothelial damage, two factors that impact aGVHD outcomes but are absent from the current risk stratification models.

Original languageEnglish (US)
Pages (from-to)172-175
Number of pages4
JournalBone marrow transplantation
Issue number2
StatePublished - Feb 1 2016

Bibliographical note

Publisher Copyright:
© 2016 Macmillan Publishers Limited All rights reserved.


Dive into the research topics of 'A risk-adapted approach to acute GVHD treatment: Are we there yet?'. Together they form a unique fingerprint.

Cite this